Innovative and Applied Emerging Technologies in Biospecimen Science (R21)

Post Date

December 15th 2008

Application Due Date

September 30th 2009

Funding Opportunity Number

RFA-CA-09-004

CFDA Number(s)

93.392
93.393
93.394
93.395
93.396

Funding Instrument Type(s)

Grant

Funding Activity Categories

Education
Health

Eligibility Categories

State Governments
Public and State Controlled Institutions of Higher Education
Non-Profits With 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Non-Profits Without 501 (c) (3) Status With The IRS (Except Higher Education Institutions)
Private Institutions of Higher Education
For-Profit Organizations (Except Small Businesses)
Small Businesses
Other

Other Eligible Applicants include the following: Eligible Agencies of the Federal Government; Non-domestic (non-U.S.) Entities (Foreign Organizations); U.S. Territory or Possession.

Funding

• Estimated Total Funding:

  $1000000

• Award Range:

  $None - $275000

Grant Description

Purpose. This Funding Opportunity Announcement (FOA) issued by the National Cancer Institute (NCI), National Institutes of Health (NIH), solicits grant applications proposing exceptionally innovative, high risk, original and/or unconventional exploratory research projects focused on the inception and early stage development of highly innovative cancer-relevant technologies for biospecimen science. The overall goal is to develop and evaluate technologies capable of interrogating and/or maximizing the quality and utility of biospecimens for molecular analyses with minimal invasiveness or compromise to donor/patient health. This FOA will also support the development of tools, devices, instrumentation, and associated methods to assess sample quality, preserve/protect sample integrity, and establish verification criteria for quality assessment/quality control and handling under diverse conditions. Projects must clearly demonstrate potential to produce a major impact in the area of biospecimen science.This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program. Several IMAT FOAs of identical or closely related scientific scope using various funding mechanisms are available. To facilitate selection, a separate Notice in the NIH Guide for Grants and Contracts provides brief cross-comparison and links to all the IMAT FOAs. See NOT-CA-09-007. Mechanism of Support. This FOA will utilize the R21 grant mechanism and runs in parallel with a FOA of identical scientific scope, RFA-CA-09-005, that solicits applications under the NIH Exploratory/Developmental Phase II Research Grant (R33) award mechanism.

Contact Information

• Agency

  Department of Health and Human Services

• Office:

  National Institutes of Health

• Agency Contact:

  NIH OER Webmaster
  FBOWebmaster@OD.NIH.GOV
  

• Agency Mailing Address:

  If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

• Agency Email Address:

  FBOWebmaster@OD.NIH.GOV

• More Information:

  http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-09-004.html